For many healthcare and life sciences companies entering the GCC, appointing a local distributor remains the default route to market. In jurisdictions such as the UAE and Saudi Arabia, local partners play a central role in regulatory navigation, market access, and operational execution. At the outset, these relationships are often framed as collaborative and well aligned, with assurances around capability, coverage, and regulatory experience.
In practice, however, the most significant risks tend to emerge later, when the relationship no longer works and the principal needs flexibility to exit, restructure, or regain control.
Early optimism and the due diligence gap
One of the most common issues we see in practice is insufficient diligence at the appointment stage, particularly around operational capability and regulatory track record. Initial discussions with prospective distributors are often persuasive. Capabilities are described confidently, regional reach is presented as seamless, and regulatory experience is emphasised.
It is not uncommon, however, for principals to discover after appointment that:
- operational capacity is overstated;
- regulatory expertise is more limited than advertised;
- market relationships are personal rather than institutional; or
- the distributor’s focus is diluted across competing portfolios.
Once contractual and regulatory dependencies are in place, correcting course becomes materially harder. In the healthcare sector, where product registrations, import licences, and pharmacovigilance systems are tightly linked to the local partner, the cost of a poor appointment decision can be high.
The regional distributor model and its consequences
A further complexity arises from the common regional distributor model. While the GCC is often treated commercially as a single region, it is not a harmonised regulatory market. A distributor appointed on a regional basis will frequently need to appoint one or more local sub-distributors in individual countries to operate lawfully.
This creates a spectrum of outcomes:
- some principals retain meaningful control, requiring consent and diligence for each sub-distributor;
- others delegate this entirely, only to discover later which entities are operating in their name; and
- in some cases, principals are required to enter into direct local distribution agreements with their sub-distributors, for example to satisfy product registration or regulatory requirements, particularly in Saudi Arabia.
Where these downstream arrangements are not carefully managed, principals may find themselves exposed to registrations, regulatory filings, or statutory protections they did not anticipate.
Agency law exposure in the UAE and Saudi Arabia
The most acute leverage issues arise where distribution arrangements are registered and attract statutory protections.
In the UAE, registered commercial agency arrangements benefit from well-established statutory protections under its Commercial Agencies Law. Termination is restricted, compensation may be payable, and deregistration is typically within the control of the registered agent. In practice, this can prevent principals from appointing replacement distributors or restructuring their market presence without the incumbent’s cooperation.
Saudi Arabia also has a formal Commercial Agency Law, under which qualifying distribution arrangements are registered with the Ministry of Commerce. Registered agents and distributors benefit from statutory protections, including restrictions on termination and potential compensation or indemnity obligations. While the Saudi regime differs in structure from the UAE’s, the practical effect can be similar once an arrangement is registered.
In both jurisdictions, the agency law analysis is often compounded by regulatory dependencies, particularly in the healthcare sector. Product registrations, import licences, pharmacovigilance responsibilities, and marketing authorisations may be tied to the local distributor. Even where the legal position appears clear on paper, the practical reality is that regulatory cooperation is required to effect a clean exit.
Compensation risk, even in breach scenarios
One of the most difficult issues for principals to accept is that compensation exposure is not limited to so-called “no-fault” terminations. In my experience advising on distributor exits in both the UAE and Saudi Arabia, principals have faced demands for, and in some cases agreed to pay, significant compensation as part of negotiated exits, even where the distributor was in material breach of its contractual obligations.
This can arise where statutory agency protections are engaged, where the breach does not meet the threshold under local law to justify immediate termination without compensation, or where regulatory dependencies materially constrain the principal’s ability to effect a clean exit. In regulated healthcare markets, distributors may also retain practical leverage through control of registrations, import permissions, or pharmacovigilance arrangements.
As a result, principals often conclude that a negotiated settlement is a more commercially viable and lower-risk option than pursuing formal dispute resolution, even where the legal merits of termination are strong. In practice, settlements are frequently used to secure deregistration, regulatory cooperation, and continuity of supply, rather than to resolve a point of principle.
A further complicating factor is what happens once a principal decides to change distributors. New prospective distributors are often keen to secure the appointment and may make ambitious promises about market access, regulatory capability, and speed to recovery. In some cases, I have seen incoming distributors offer to absorb or contribute towards compensation payments owed to the outgoing distributor, presenting this as a way to facilitate a clean transition. While commercially attractive in the moment, this can perpetuate a cycle in which structural risks are not fully addressed, and similar leverage issues resurface further down the line if the new arrangement is not carefully diligence-tested and structured. In practice, the urgency to restore market coverage can sometimes override a more forensic assessment of whether the same risks are simply being reset under a different name.
Exits in practice: settlements, transfers, and sequencing
When relationships break down, principals often find that contractual termination rights alone do not deliver a clean outcome. In practice, exits commonly involve:
- negotiated deregistration of agency arrangements;
- transfer of marketing authorisations or product registrations;
- transitional supply or wind-down arrangements;
- compensation or release payments; and
- carefully sequenced regulatory filings across multiple authorities.
These processes are rarely quick and often far more expensive than anticipated when the relationship was first established.
What experienced principals do differently
None of this means that local distributors should be avoided. They remain a commercial necessity in much of the GCC. The key is recognising that distribution arrangements in the region can have lasting legal and regulatory consequences, and that leverage is often exercised at exit, not at entry.
From experience, the most effective mitigations include:
- thorough diligence on both proposed distributors and likely sub-distributors;
- careful consideration of whether registration is required and where it occurs;
- express contractual obligations to cooperate with deregistration and regulatory transfers;
- clear treatment of marketing authorisations, product registrations, and data ownership;
- step-in rights and powers of attorney to support regulatory continuity; and
- exit mechanics that anticipate local law constraints rather than ignoring them.
These are not academic drafting points. They reflect where disputes actually arise when relationships sour.
A familiar pattern and a preventable one
Across the UAE, Saudi Arabia, and the wider GCC, the pattern is consistent: early optimism, followed by regulatory and statutory entanglement, and then a difficult unwinding process that could have been mitigated with earlier planning.
In my experience, the difference between a manageable transition and a protracted, high-stakes negotiation is often determined at appointment stage, when leverage is balanced and expectations are aligned. For healthcare and life sciences companies operating in the region, that is the moment when legal input is most valuable, not when the relationship is already under strain.
